Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Abstract

Abstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Keywords

• chronic myelomonocytic leukemia
• eculizumab
• warm autoimmune hemolytic anemia